SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
August 01, 2022 09:30 ET | SciSparc Ltd
The addition of a U.S. site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL AVIV, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE)...
Hopebridge Continues to Offer Autism Therapy Services at New Location in North Little Rock
July 31, 2022 08:00 ET | Hopebridge
LITTLE ROCK, AR, July 31, 2022 (GLOBE NEWSWIRE) -- As the prevalence of autism increases and the national focus is placed on early identification and intervention, Hopebridge Autism Therapy Centers...
Hopebridge Autism Therapy Centers foster friendships between children receiving care and their families
July 29, 2022 17:00 ET | Hopebridge
Indianapolis, July 29, 2022 (GLOBE NEWSWIRE) -- Two mothers of children receiving care at Hopebridge Autism Therapy Centers have shared how their families fostered a friendship through their sons’...
CentralReach Launches New Awards Program Recognizing Top Leaders Transforming Autism and IDD Care
July 26, 2022 10:55 ET | CentralReach
Fort Lauderdale, FL, July 26, 2022 (GLOBE NEWSWIRE) -- CentralReach, the leading provider of Autism and IDD Care software, today announced the launch of the Autism and IDD Care Awards, the...
Hopebridge Expands Clinical Excellence Through New Role Supporting BCBAs
July 11, 2022 07:00 ET | Hopebridge
Indianapolis, IN, July 11, 2022 (GLOBE NEWSWIRE) -- Hopebridge Autism Therapy Centers recently furthered its commitment to expand access to quality, value-based services for children with autism...
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome
July 08, 2022 08:30 ET | SciSparc Ltd
TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility
July 07, 2022 08:30 ET | SciSparc Ltd
The new facility will serve the JV’s development of potential cancer drugs TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a...
Little Leaves Behavioral Services Earns Three-Year Reaccreditation From Behavioral Health Center of Excellence
July 06, 2022 10:26 ET | Little Leaves
SILVER SPRING, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Little Leaves Behavioral Services, a leading provider of center-based Applied Behavioral Analysis (ABA) for children, today announced it has...
SciSparc Board of Directors to Promote Buyback Program of up to $1 Million
July 06, 2022 08:30 ET | SciSparc Ltd
TEL AVIV, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of...
Easterseals Massachusetts Chooses CentralReach’s avail® Solution to Help Empower Individuals with Disabilities at Work and Home
June 29, 2022 11:03 ET | CentralReach
Fort Lauderdale, FL, June 29, 2022 (GLOBE NEWSWIRE) -- Easterseals Massachusetts is excited to announce it has selected CentralReach’s avail® solution to help support individuals with autism and...